¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"glucose related protein"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • glucose intolerance
    Æ÷µµ´ç¸ø°ßµõ(Áõ), Æ÷µµ´çºÒ³»¼º
  • glucose lactate cycle
    Æ÷µµ´çÁ¥»ê¿°È¸·Î
  • glucose tolerance test
    ´çºÎÇϰ˻ç
  • glucose-6-phosphatase
    Æ÷µµ´çÀ°ÀλêÈ­È¿¼Ò, ±Û·çÄÚ¿À½º-6-Æ÷½ºÆÄŸ¾ÆÁ¦
  • glucose-6-phosphate dehydrogenase
    6-ÀλêÆ÷µµ´çÅ»¼ö¼ÒÈ¿¼Ò
  • insulin-to-glucose ratio
    Àν¶¸°´ëÆ÷µµ´çºñ
  • liquid glucose
    ¾×üÆ÷µµ´ç
  • oral glucose tolerance test
    °æ±¸Æ÷µµ´ç³»¼º°Ë»ç
  • urine glucose
    ¿ä´ç
  • antifreeze protein
    Ç×µ¿°á´Ü¹éÁú
  • antiviral protein
    Ç×¹ÙÀÌ·¯½º´Ü¹éÁú
  • adherence protein
    ºÎÂø´Ü¹éÁú
  • androgen binding protein
    ¾Èµå·Î°Õ°áÇմܹéÁú
  • Bence Jones protein
    º¥½º-Á¸½º´Ü¹éÁú
  • coat protein
    ¿ÜÇǴܹéÁú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • glucose fluctuation
    Æ÷µµ´çº¯µ¿
  • glucose
    Æ÷µµ´ç, ±Û·çÄÚ½º
  • glucose-6-phosphatase
    Æ÷µµ´çÀ°ÀλêÈ­È¿¼Ò, ±Û·çÄÚ¿À½º-6-Æ÷½ºÆÄŸ¾ÆÁ¦
  • glucose monitoring
    Æ÷µµ´ç°¨½Ã
  • glucose insulin tolerance test
    Æ÷µµ´çÀν¶¸°°ßµõ°Ë»ç
  • glucose tolerance test
    Æ÷µµ´ç°ßµõ°Ë»ç
  • liquid glucose
    ¾×üÆ÷µµ´ç
  • insulin-to-glucose ratio
    Àν¶¸°Æ÷µµ´çºñÀ²
  • oral glucose tolerance test
    °æ±¸Æ÷µµ´çºÎÇϰ˻ç
  • adherence protein
    ºÎÂø´Ü¹é
  • antifreeze protein
    Ç×µ¿°á´Ü¹éÁú
  • protein binding
    ´Ü¹é°áÇÕ
  • carrier protein
    ¿î¹Ý´Ü¹é, ¿î¹Ý´Ü¹éÁú
  • catabolite activating protein
    ÀÌÈ­»ê¹°È°¼ºÈ­´Ü¹é
  • coat protein
    ¿ÜÇǴܹé
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Glucose tolerance
    ³»´ç·Â(Ò±ÓØÕô)
  • Glucose transporters
    ´çÀü´Þü(ÓØîîÓ¹ô÷)
  • Glucose-6-phosphate dehydrogenase
    ±Û·çÄÚ¿À½º-6-Àλê(×òß«)Å»¼ö¼ÒÈ¿¼Ò(÷­â©áÈý£áÈ)
  • Glucose-galactose malabsorption syndrome
    ±Û·çÄÚ¿À½º-°¥¶ôÅ佺Èí¼öÀå¾ÖÁõÈıº(ýåâ¥î¡äôñøý¦ÏØ)
  • Sabouraud glucose agar [medium]
    »çºê·Î Æ÷µµ´çÇÑõ¹èÁö
  • UDPG=£¾uridine diphosphate glucose
    ÀÌÀλê¿ì¸®µò±Û·çÄÚ¿À½º.
  • glucose 3 phosphatase =G-3-P
    ±Û·çÄÚ¿À½º-3-Æ÷½ºÆÄŸÁ¦.
  • glucose 6 phosphatase =G-6-P
    ±Û·çÄÚ¿À½º-6-Æ÷½ºÆÄŸÁ¦.
  • glucose 6 phosphatase deficiency hepa
    ±Û·çÄÚ¿À½º-6 -ÀÎ»ê °áÇ̰£½ÅÇü´ç
  • glucose 6 phosphate
    ±Û·çÄÚ¿À½º-6-Àλê.
  • glucose 6 phosphate dehydrogenase =G 6 PD
    ±Û·çÄÚ¿À½º 6Àλê Å»¼ö ¼ÒÈ¿¼Ò, ±Û·çÄÚ¿À½º-6-ÀÎ»ê µ¥È÷µå·Î°Ô³ªÁ¦.
  • glucose 6 phosphate dehydrogenase def
    ±Û·çÄÚ¿À½º-6-Àλê Å»¼ö¼Ò È¿¼Ò°á
  • glucose dehydrogenase
    ±Û·çÄÚ¿À½ºÅ»¼ö¼ÒÈ¿¼Ò, ±Û·çÄÚ¿À½ºµ¥È÷µå·Î°Ô³ªÁ¦.
  • glucose effect
    Æ÷µµ´çÈ¿°ú
  • glucose equivalent
    ±Û·çÄÚ¿À½º´ç·®.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hallucinogen-related disorder
    ȯ°¢Á¦ °ü·ÃÀå¾Ö(º´)(ü³ÊÆð¥Î¼Ö¤î¡äô)
  • malnutrition related diabetes mellitus
    ¿µ¾ç ½ÇÁ¶¼º ´ç´¢(º´).
  • opioid-related disorder
    ¾ÆÆí¾çÁ¦Á¦ °ü·ÃÀå¾Ö(μ֤î¡äô)(º´)
  • parathyroid hormone-related peptide
    ºÎ°©»ó¼±(ÜùË£ßÒàÍ)È£¸£¸ó¿¬°ü(¡­æáμ)ÆéŸÀ̵å
  • polysubstance-related disorder
    º¹ÇÕ¹°Áú°ü·ÃÀå¾Ö(º´)
  • related
    ±ÙÄ£(ÐÎöÑ)ÀÇ.
  • sleep-related disorders
    ¼ö¸é°ü·ÃÀå¾Ö(º´)
  • steroid-related disorders
    ½ºÅ×·ÎÀÌµå °ü·ÃÀå¾Ö(º´).
  • stress-related disorders
    ½ºÆ®·¹½º °ü·ÃÀå¾Ö(º´).
  • tobacco-related disorders
    Åä¹ÙÄÚ(´ã¹è)°ü·ÃÀå¾Ö(~º´).
  • transfusion-related
    ¼öÇ÷-¿¬°üÀÇ
  • blood glucose
    Ç÷´ç(úìÓØ).
  • chopped meat glucose broth
    Àú¹Î°í±â-Æ÷µµ´ç ¾×ü¹èÁö
  • cortisone glucose tolerance test =CGTT
    ÄÚ¸£Æ¼¼Õ Æ÷µµ´ç ºÎÇϽÃÇè(¡­øã Ô¬ÓØÝ¶ùÃãËúÐ).
  • d-Glucose ceramide
    d-Æ÷µµ´ç ¼¼¶ó¹Ìµå
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • uridine diphosphate glucose
    À¯¸®µò ÀÌÀλê(ì£×òß«) ±Û·çÄÚ½º
  • accelerator protein
    ÃËÁø´Ü¹éÁú (õµòäÓ±ÛÜòõ)
  • acyl-carrier protein
    ¾Æ½Ç¿î¹Ý ´Ü¹éÁú (ê¡ÚæÓ±ÛÜòõ)
  • ada protein
    ada ´Ü¹éÁú
  • adhesion protein
    ºÎÂø´Ü¹éÁú(ݾó·Ó±ÛÜòõ)
  • aldosterone-induced protein
    ¾Ëµµ½ºÅ×·ÐÀ¯µµ ´Ü¹éÁú(ë¯ÓôÓ±ÛÜòõ)
  • A myeloma protein
    °ñ¼öÁ¾´Ü¹éÁú(ÍéâÐðþÓ±ÛÜòõ) A
  • androgen-binding protein
    ¾Èµå·ÎÀü°áÇÕ(Ì¿ùê) ´Ü¹éÁú(Ó±ÛÜòõ)
  • animal protein factor
    µ¿¹°´Ü¹éÁúÀÎÀÚ(ÔÑÚªÓ±ÛÜòõì×í­)
  • anion-transport protein
    À½À̿¿î¹Ý(ê¡Úõ) ´Ü¹éÁú(Ó±ÛÜòõ)
  • antifreeze protein
    Ç×°áºù´Ü¹éÁú(ù÷̿޼ӱÛÜòõ)
  • antitumor protein
    Ç×Á¾¾ç ´Ü¹éÁú(ù÷ðþåËÓ±ÛÜòõ)
  • antiviral protein
    Ç×(ù÷) ¹ÙÀÌ·¯½º ´Ü¹éÁú(Ó±ÛÜòõ)
  • A protein
    A ´Ü¹éÁú(Ó±ÛÜòõ)
  • azo-dye protein
    ¾ÆÁ¶»ö¼Ò ´Ü¹éÁú(ßäáÈÓ±ÛÜòõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MAP malignant atrophic papulosis; mandibular angle plane; maturation-activated protein; maximal aerobic ...
MBP major basic protein; maltose-binding protein; management by policy; mannose-binding protein; mean bl...
RP radial pulse; radiopharmaceutical; rapid processing [of film]; Raynaud phenomenon; reactive protein;...
GA Gamblers Anonymous; gastric analysis; gastric antrum; general anesthesia; general angiography; gener...
HGO hepatic glucose output; human glucose output
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LRP LDL receptor related protein
LRP LDL-R-related protein
LRP Lipoprotein Receptor-related Protein
LRP Lung Resistance-related Protein
MRP MARCKS-related protein
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acute phase protein
    ±Þ¼º±â ´Ü¹éÁú
    °¨¿°À̳ª Á¶Á÷ ¼Õ»óÀÌ ÀÖÀ» ¶§ Á¤»óº¸´Ù 2-100¹è Á¤µµ Áõ°¡ÇÏ´Â Ç÷Àå ´Ü¹éÁúÀ» ÃÑĪÇÏ¿© APP¶ó°í ÇÏ¸ç ¼±Ãµ¼º ¸é¿ª¿¡ °ü¿©ÇÑ´Ù.
  • androgen binding protein
    ³²¼º È£¸£¸ó °áÇÕ ´Ü¹é
  • bacterio protein
    ¼¼±Õ ´Ü¹éÁú
  • body protein
    ü´Ü¹é, ü´Ü¹éÁú
  • C-reactive protein
    C-¹ÝÀÀ ´Ü¹é, C-¹ÝÀÀ¼º ´Ü¹éÁú
  • cellular retinoid acid-binding protein
    ¼¼Æ÷³» ·¹Æ¼³ëÀ̵å»ê °áÇÕ ´Ü¹é
  • chromatographic protein separation
    Å©·Î¸¶Åä±×·¡Çǹý ´Ü¹é ºÐ¸®
  • D-myeloma protein
    D-°ñ¼öÁ¾ ´Ü¹é
    ¸é¿ª ±Û·ÎºÎ¸°ÀÇ ÇÑ ºÎ·ùÀÎ IgD¸¦ »ý»êÇÏ´Â °ñ¼öÁ¾¿¡¼­ ¸¸µé¾îÁø ´Ü¹éÁú.
  • eosinophil protein X
    È£»ê±¸ ´Ü¹é X
  • estrogen receptor protein
    ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ´Ü¹éÁú
  • hapten-protein conjugate
    ÇÕÅÙ ´Ü¹é °áÇÕ¹°
  • heat-aggregated protein
    ¿­ ÀÀÁý ´Ü¹é
  • hepatic protein
    °£ ´Ü¹é, °£ ´Ü¹éÁú
    °£ÀÇ ´Ü¹éÁú.
  • high protein diet
    °í´Ü¹é ½ÄÀÌ
  • membrane protein
    ¸· ´Ü¹éÁú
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
risks, obesity-related Obesity increases the risk of developing a number of diseases including: type 2 (adult-onset) diabetes high blood pressure (hypertension) stroke (cerebrovascular accident or cva) heart attack (myocardial infarction or mi) heart failure (congestive heart failure) cancer (only certain forms such as prostate and colon cancer) gallstones and gall bladder disease (cholecystitis) gout and gouty arthritis osteoarthritis (degenerative arthritis) of the knees, hips, and the lower back sleep apnea (failure to breath normally during sleep, lowering blood oxygen) pickwickian syndrome (obesity, red face, underventilation, and drowsiness)
(12 Dec 1998)
cocaine-related disorder <psychiatry> Disorders related or resulting from use of cocaine.
(12 Dec 1998)
movement-related pain <symptom> A type of breakthrough pain that is related to specific activity, such as eating, defecation, socialising or walking. Also referred to as incident pain.
(16 Dec 1997)
criterion-related validity The degree of effectiveness with which performance on a test or procedure predicts performance in a real-life situation; e.g., a good correlation between a score on an intelligence test such as the Scholastic Aptitude Test and one's 4-year college grade point average.
(05 Mar 2000)
prosthesis-related infections Infections resulting from the implantation of prosthetic devices. The infections may be acquired from intraoperative contamination (early) or haematogenously acquired from other sites (late).
(12 Dec 1998)
src-related intestinal kinase <enzyme> An intracellular epithelial cell tyrosine kinase; shares 80% homology with human tyrosine kinase brk; has 451 amino acid residues; amino acid sequence given in first source
Registry number: EC 2.7.1.-
Synonym: sik protein, sik gene product
(26 Jun 1999)
substance-related disorders These non-psychotic disorders include those related to the taking of a drug of abuse (including alcohol), to the side effects of a medication, and to toxin exposure.
(12 Dec 1998)
diabetes related peptide <hormone, protein> Peptide of 37 amino acids that selectively inhibits insulin stimulated glucose uptake in muscle. Structurally related to calcitonin gene-related peptide.
(15 Oct 1997)
diagnosis-related group A classification of patients by diagnosis or surgical procedure (sometimes including age) into major diagnostic categories (each containing specific diseases, disorders, or procedures) for the purpose of determining payment of hospitalization charges, based on the premise that treatment of similar medical diagnoses generate similar costs.
A scheme for billing for medical and especially hospital services by combining diseases into groups according to the resources needed for care, arranged by diagnostic category. A dollar value is assigned to each group as the basis of payment for all cases in that group, without regard to the actual cost of care or duration of hospitalization of any individual case, as a mechanism to motivate health-care providers to economise.
(05 Mar 2000)
diagnosis-related groups A system for classifying patient care by relating common characteristics such as diagnosis, treatment, and age to an expected consumption of hospital resources and length of stay. Its purpose is to provide a framework for specifying case mix and to reduce hospital costs and reimbursements and it forms the cornerstone of the prospective payment system.
(12 Dec 1998)
diseases, obesity-related Obesity increases the risk of developing a number of diseases including: Type 2 (adult-onset) diabetes High blood pressure (hypertension) Stroke (cerebrovascular accident or CVA) Heart attack (myocardial infarction or MI) Heart failure (congestive heart failure) Cancer (only certain forms such as prostate and colon cancer) Gallstones and gall bladder disease (cholecystitis) Gout and gouty arthritis Osteoarthritis (degenerative arthritis) of the knees, hips, and the lower back Sleep apnea (failure to breath normally during sleep, lowering blood oxygen) Pickwickian syndrome (obesity, red face, underventilation, and drowsiness).
(12 Dec 1998)
obesity-related diseases Obesity increases the risk of developing a number of diseases including: type 2 (adult-onset) diabetes high blood pressure (hypertension) stroke (cerebrovascular accident or cva) heart attack (myocardial infarction or mi) heart failure (congestive heart failure) cancer (only certain forms such as prostate and colon cancer) gallstones and gall bladder disease (cholecystitis) gout and gouty arthritis osteoarthritis (degenerative arthritis) of the knees, hips, and the lower back sleep apnea (failure to breath normally during sleep, lowering blood oxygen) pickwickian syndrome (obesity, red face, underventilation, and drowsiness).
(12 Dec 1998)
opioid-related disorders Disorders related or resulting from abuse or mis-use of opioids.
(12 Dec 1998)
event-related potentials, p300 A late-appearing component of the event-related potential. P stands for positive voltage potential and 300 represents 300 millisecond poststimulus. Its amplitude increases with unpredictable, unlikely, or highly significant stimuli and thereby constitutes an index of mental activity.
(12 Dec 1998)
fos-related antigen <molecular biology> A group of phosphoproteins found in the cell nucleus which are structurally similar to the fos oncogene's gene product.
(06 Mar 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á